Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proleukin in HIV-1 Infection with CD4 >= 300
NCT00000949Phase 3
Key facts
- Status
- Completed
- Countries
- 1
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Cytokines & Interferons
- Drugs
- aldesleukin
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 3, randomised, open-label trial of aldesleukin in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: HIV Viral Burden and CD4+ Cell Count. Status: completed.
02
Design
3 arms- Study design
- RandomizedOpen-label
rIL-2 Dose 1
Subcutaneous rIL-2 Dose 1 + Anti-HIV therapy
rIL-2 Dose 2
Subcutaneous rIL-2 Dose 2 + Anti-HIV therapy
Control
Anti-HIV therapy alone
03
Who it enrols
HIV-positive adults with CD4 count >= 300 cells/mm3 on anti-HIV therapy. Excludes patients with history of progressive diseases, severe autoimmune/inflammatory disease, Crohn's disease, or prior rIL-2 therapy.
04
Endpoints
Primary
HIV Viral Burden
CD4+ Cell Count
Beyond the preview
Go deeper on NCT00000949.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000949.